FDAsafety guidance83% confidence
FDA Rare Disease Innovation Hub
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to nontuberculous mycobacterial lung disease patients.
Regulatory Analysis
FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.
Supporting Context
- Therapeutic area
- Pulmonology · Nontuberculous Mycobacterial Lung Disease
- Sub-indication
- General
Related signal: Inhaled 3% hypertonic saline shows promise for antibiotic-naïve NTM lung disease